Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001558370-20-010480
Filing Date
2020-08-13
Accepted
2020-08-13 07:03:59
Documents
42
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 6-K rdhl-20200630x6k.htm 6-K 14360
2 EX-1 rdhl-20200630ex1f0c5a7a5.htm EX-1 274723
3 EX-2 rdhl-20200630xex2.htm EX-2 524225
4 GRAPHIC rdhl-20200630ex1f0c5a7a5001.jpg GRAPHIC 5850
  Complete submission text file 0001558370-20-010480.txt   3288694

Data Files

Seq Description Document Type Size
5 EX-101.INS rdhl-20200630.xml EX-101.INS 606117
6 EX-101.SCH rdhl-20200630.xsd EX-101.SCH 38631
7 EX-101.CAL rdhl-20200630_cal.xml EX-101.CAL 36517
8 EX-101.DEF rdhl-20200630_def.xml EX-101.DEF 111934
9 EX-101.LAB rdhl-20200630_lab.xml EX-101.LAB 302554
10 EX-101.PRE rdhl-20200630_pre.xml EX-101.PRE 203827
Mailing Address 21 HA'ARBA'A STREET TEL AVIV L3 64739
Business Address 21 HA'ARBA'A STREET TEL AVIV L3 64739 972-3-541-3131
RedHill Biopharma Ltd. (Filer) CIK: 0001553846 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3
Type: 6-K | Act: 34 | File No.: 001-35773 | Film No.: 201097170
SIC: 2834 Pharmaceutical Preparations